Hidetoshi Nakashima

Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.

To the Editor: As hemojuvelin hemochromatosis is a severe subtype of hemochromatosis, in affected persons, intensive iron removal is essential to prevent the irreversible multiorgan damage (1). Although phlebotomy is the standard treatment, compliance with this therapy can vary. The once-daily, oral iron chelator deferasirox (DFX) (Exjade; Novartis Pharma AG, Basel, Switzerland) is an option to phlebotomy treatment for patients with hemochromatosis and iron overload, although the safety and efficacy of DFX remain unproven for this option (2, 3). Herein, we report the case of a 29-yr-old Japanese man with hemojuvelin hemochromatosis who was treated with DFX. He was diagnosed with hemochromatosis at the age of 13. He was treated with phlebotomy, but discontinued treatment at the age of 20. After 9 yrs, he visited our hospital because of symptomatic heart failure. He had no history of excessive iron ingestion, alcohol consumption, or transfusion. He was not married and did not have children. One of his brothers had been diagnosed with type 1 diabetes mellitus at the age of 31. His mother was healthy and his father suffered from hepatic dysfunction and arrhythmia; however, iron deposition was not evident. Consanguinity was not known to be present in this kinship. There was no sign of hepatosplenomegaly. White blood cells (WBC) were 2.8 · 10 ⁄L, red blood cells were 3.76 · 10 ⁄L, reticulocytes were 26.3 · 10 ⁄L, and platelets were 99.0 · 10 ⁄L. Aspartate transaminase (AST) level was 83 U ⁄L, and alanine transaminase (ALT) level was 80 U ⁄L. Serum ferritin was 6624 ng ⁄mL, serum iron was 306 lg ⁄dL, and the total iron binding capacity was 324 lg ⁄dL. Bone marrow aspiration showed the nucleated cell count to be 20 000 ⁄ lL. Iron deposition was observed in macrophages, and no dysplastic blood cells were observed. Cardiac and liver iron overload was evident on magnetic resonance imaging, and the left ventricular ejection fraction (EF) was 24% by echocardiography. The genes analyzed in this patient included HFE, HJV, human antimicrobial peptide (HAMP), transferrin receptor 2 (TFR2), and SLC40A1 (4–6). The protocol was approved by the ethics committees in both Showa University Hospital and Aichi Gakuin University. The patient provided written informed consent for genetic testing, measurement of all biochemical markers, and treatment with DFX according to the Declaration of Helsinki. Molecular analysis revealed a homozygous genotype 515_6insC mutation in exon 3 of HJV, without detectable mutations of HFE, HAMP, TFR2, and SLC40A1 genes. The novel mutation predicts a stop signal at codon 196 (D172fsX196). The patient was treated daily with DFX 10 mg ⁄kg. Serum liver enzyme levels and ferritin decreased rapidly. The symptoms of the cardiac failure disappeared, and the EF improved up to 40%. At 28 weeks, the platelet increased to the normal range, and reticulocyte and WBCs increased further to 34.9 · 10 and 4.9 · 10 ⁄L, respectively (Fig. 1). The DFX dose of 10 mg ⁄kg ⁄day reduced the serum levels of ferritin and transaminases. It is a lower dose than that generally recommended for patients with transfusion-induced iron overload (2, 3, 7). He continued iron chelation therapy and did not experience any adverse events. This suggests that a small dose of DFX is effective to remove iron deposits in several organs, although iron accumulation in the tissues was not directly evaluated. During DFX treatment, we observed a substantial increase in WBCs, reticulocytes, and platelet counts, although the levels were below normal range at diagnosis. The mechanisms by which iron chelation may lead to hematologic improvement are unclear. He did not receive any specific therapeutics or blood transfusion during this period. Decreased splenic consumption of blood cells was not a plausible explanation for these increases, because splenomegaly was not evident throughout the clinical course. In some patients with myelodysplastic syndrome, iron chelation therapy appears to stimulate hematopoiesis, leading to a reduction or even complete weaning from the need for transfusion (8, 9). Iron overload itself exhibits a suppressive effect on erythroid progenitors and seems to increase transfusion requirement (10). Iron chelators promote iron release from storage sites, facilitating its usage for hematopoietic tissues. Iron excess is associated with increased oxidative stress. It would appear that the level of oxidative stress is directly responsible for organ dysfunction, including bone doi:10.1111/j.1600-0609.2011.01693.x European Journal of Haematology 87 (467–469)

CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma.

In diffuse large B‐cell lymphoma (DLBCL), a CD20‐negative relapse is clinically significant because it is associated with chemo‐refractory phenotypes and loss of a therapeutic target. The alteration of the CD20 gene is reported as infrequent in CD20‐negative relapse in B‐cell lymphoma. We established a DLBCL cell line with loss of CD20 expression (SD07) from a patient at CD20‐negative relapse. She was initially diagnosed with CD20‐positive DLBCL and received repeated immuno‐chemotherapy that included rituximab. SD07, which has an immunoglobulin κ rearrangement identical to that of lymphoma cells at CD20‐negative relapse, showed homozygous deletion of the CD20 gene with loss of the copy number of 11q12. SD07 is the first case in which it is proven that the loss of CD20 expression in relapsed DLBCL is the result of deletion of the CD20 gene. Deletion of the CD20 gene is a molecular mechanism of CD20‐negative relapse in a subset of DLBCL.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation

Patients with Ph chromosome negative myeloproliferative disease (Ph-MPD) have an increased risk of vascular complications. It remains controversial whether patients with the JAK2 V617F mutation (V617F) exhibit increased risk, while recent growing evidence has shown a critical role for V617F in clonal erythropoiesis in Ph-MPD. We studied 53 patients with Ph-MPD especially in relation to megakaryopoiesis, the thrombotic complications and the presence of V617F. Using novel mutation-specific PCR which is a highly sensitive PCR-based assay for detection of JAK2 mutated allele(s), we identified V617F in 38 Ph-MPD, which include 13 polycythemia vera (PV), 23 essential thrombocythemia (ET) and 2 chronic idiopatic myelofibrosis. The numbers of megakaryocytes were significantly increased in PV and ET patients with V617F, but the platelet counts were slightly lower. Although statistically not significant, the incidence of thrombotic events was higher in the group with V617F compared to in those without the mutation. Agonist-induced in vitro platelet aggregation and platelet adhesion were not affected by the presence of this mutation. Nonetheless, we found a hypercoagulable state in Ph-CMPD with V617F by employing whole blood thromboelastography. It suggests pre-thrombotic tendencies in CMPD are complex and JAK2 V617F mutation might have a role in vivo blood coagulation by altering not only the number, but function(s) of all three myeloid cells, including red blood cells, white blood cells and platelets in Ph-CMPD.

p53 Protein Expression in Chronic Myelomonocytic Leukemia-1 Correlates with Progression to Leukemia and a Poor Prognosis

CMML-1 is controversial. Herein, we performed a retrospective study of the clinical features of patients with CMML-1 in a single institution. In our institution, 20 patients with CMML-1 reclassified retrospectively based on the WHO (2008) criteria and diagnosed as having CMML based on the FAB or WHO (2001) classification were included in this study. Rearrangement of PDGFRA or PDGFRB was excluded in case of eosinophilia. Our series excluded cases of secondary CMML associated with therapy-related MDS/AML. Patients were followed up from 1996 to 2008. Mutational analysis was performed on DNA from BM cells from the study participants. All samples were obtained with informed consent, and the protocols were approved by our institution’s ethics committee. The clinical characteristics and laboratory data were determined by a review of medical records. Laboratory and physical examination data of all patients were obtained at diagnosis. BM aspiration and biopsy samples were taken and analyzed at diagnosis and at the time of transformation to AML. Chromosomal analyses of BM cells were performed by G-banding techniques. Hydroxyurea was used as a cytoreductive drug in some of the CMML patients. After the Chronic myelomonocytic leukemia (CMML) is characterized by persistent monocytosis and by features of a myeloproliferative neoplasm and a myelodysplastic syndrome (MDS). CMML is subdivided into CMML-1, with

Histopathological bone marrow changes after reduced‐intensity hematopoietic stem cell transplantation for follicular lymphoma involving bone marrow

Allogeneic stem cell transplantation (allo‐SCT) is used as curative therapy for malignant lymphoma, and reduced‐intensity hematopoietic stem cell transplantation (RIST) is sometimes performed to avoid the toxicity and mortality associated with myeloablative allo‐SCT. RIST is generally preferred for elderly patients with malignant lymphoma. A 62‐year‐old woman with follicular lymphoma (FL) involving bone marrow (BM) suffered relapse after autologous SCT. RIST was performed; cells were from an unrelated, fully human leukocyte antigen‐matched donor. To study the hematopoietic reconstitution, BM biopsy specimens that were obtained at different times after RIST, were evaluated. Engraftment of donor cells was observed on days 19 and 48 after RIST, and residual FL in BM had completely disappeared by day 73 after RIST. This is the first report to document histological BM regeneration after RIST and disappearance of FL involving the BM.